What's Happening?
The European Medicines Agency (EMA) has introduced a proposal aimed at reducing the use of animals in medicine development by utilizing virtual models. This initiative involves the use of virtual control groups (VCGs) instead of rats in dose range finding
toxicology testing. The EMA's draft qualification opinion outlines the principles for accepting evidence generated through VCGs in regulatory filings, with the consultation period open until May 12. This proposal is part of a series of new approach methodologies (NAMs) intended to minimize animal testing. The application for VCGs was submitted by Synapse Research Management Partners in collaboration with five pharmaceutical companies, marking a significant milestone for the VICT3R consortium, which is dedicated to reducing animal use in toxicology research.
Why It's Important?
The EMA's move to incorporate virtual models in toxicology testing represents a significant shift towards more ethical and human-centric research methodologies. By reducing reliance on animal models, the initiative aims to improve the relevance and predictability of non-clinical testing, potentially leading to more efficient and ethically responsible medicine development. This approach aligns with global trends among regulatory authorities, including the US FDA, which are exploring technologies like organ-on-chip devices and computer modeling to better reflect human biology. The adoption of virtual models could lead to a substantial decrease in the number of animals used in medical research, addressing ethical concerns and enhancing the accuracy of drug reaction predictions.
What's Next?
The EMA's proposal is currently open for consultation, with feedback expected to shape the final qualification opinion. If successful, this initiative could pave the way for broader adoption of virtual models in toxicology testing across the pharmaceutical industry. Regulatory authorities worldwide may follow suit, potentially leading to a global reduction in animal testing. Pharmaceutical companies and research institutions are likely to invest in developing and validating these virtual models, which could become a standard practice in medicine development. The VICT3R consortium and other stakeholders will continue to advocate for the integration of NAMs in regulatory processes.
